AK-ALASKA-CARGO
25.1.2021 06:03:09 CET | Business Wire | Press release
Alaska Cargo and Cold Storage, LLC (ACCS) and the State of Alaska executed a 55-year lease agreement at Ted Stevens Anchorage International Airport (ANC), marking a major milestone in the development of a more than 700,000-square-foot, climate-controlled warehouse facility. With 32.5 million cubic feet of capacity, the facility will provide ANC with a critical piece of infrastructure at the world’s sixth-busiest cargo airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210124005094/en/
“This project will improve shipping to and through Anchorage, create jobs, and show the world that Alaska is open for business,” said Alaska Gov. Mike Dunleavy. “We’re excited about the potential this integral piece of the global cold chain has to make Ted Stevens Anchorage International Airport and Alaska a more attractive place for global companies to do business.”
ACCS is a joint venture of industrialist Chad Brownstein and McKinley Capital Management, LLC (McKinley Capital), which is led by Rob Gillam. Brownstein is the founder of Rocky Mountain Resources which has aggregated an industrial complex throughout the Mountain West. Gillam is the chief executive officer and chief investment officer at McKinley Capital.
Located on the Great Circle Route, ANC is within 9.5 hours of 90% of key markets in Asia, Europe and North America. Illustrating this importance, during COVID-19 air travel disruptions, ANC was the busiest airport in the world on select days in 2020. Historically, a limited supply of warehouse and transfer facilities at ANC designates ANC’s air cargo support as “gas-and-go.” Brownstein and Gillam say the development of ACCS — located runway-adjacent and within a Foreign Trade Zone — will position ANC to be transformed into a key cold chain transfer hub for global air cargo carriers.
“We believe Alaska offers world-class development and investment opportunities,” said Gillam. “ACCS is a clear instance. There are many industries that require cold storage. One example is Alaska seafood, one of Alaska’s biggest exports, and it’s shipped globally. For decades, almost no value-added or fresh production occurred in-state. ACCS will lead the way in changing that trend. Now, Alaska can capitalize on its valuable position as a hub between North America and Asia. We see this project as something with potential to increase air cargo traffic and spur local economic development. We’re confident ACCS will ultimately bring more dollars and jobs into Anchorage and across the state.”
“The addition of this facility with cold storage capabilities brings new opportunity for the global distribution tenants and customers already benefitting from the unique features of the Anchorage trade and tariff exemptions,” said Brownstein. “The facility will serve as the cold storage gateway between the Americas, Asia, and Europe, and further integrate Alaska into the global cold chain.”
“Cargo carriers and their industry partners are recognizing the advantages of operating at ANC. ACCS’s new facility will strengthen our already powerful cargo network,” said Airport Director Jim Szczesniak. “ANC offers daily, nonstop freighter service to more than 30 destinations and near daily service to an additional 20. This facility will allow perishables to be consolidated from North America and Latin America and then distributed to freighters bringing perishables closer to the consumer. Cutting the time from field or sea to the consumer will provide a better product.”
In September 2020, the U.S. Department of Transportation awarded the Alaska Energy Authority (AEA), a $21 million BUILD grant to administer in support of the ACCS project.
“It’s incredible to be a part of this project that has the potential to improve Alaska’s position on the global supply chain,” said AEA Executive Director Curtis W. Thayer. “Our partnership with the ACCS team enables AEA to deploy its expertise to assure that the best of cutting-edge technology will make the building a showpiece in energy-efficiency.”
The facility will be constructed in phases. The first phase will be roughly 190,000 square feet with plans to begin construction in the second half of 2021. When fully completed, the facility will offer cold and warm storage, quick cargo, and general warehousing options, logistics services, and auxiliary space for tenant offices.
About Alaska Cargo and Cold Storage, LLC
Alaska Cargo and Cold Storage, LLC (ACCS) is a joint venture of industrialist Chad Brownstein and McKinley Capital Management, LLC (McKinley Capital), which is led by Rob Gillam. Brownstein is the founder of Rocky Mountain Resources which has aggregated an industrial complex throughout the Mountain West. Gillam is the chief executive officer and chief investment officer at McKinley Capital. ACCS signed a 55-year ground lease with the State of Alaska to develop a secure, more than 700,000-square-foot and 32.5 million-cubic-foot, climate-controlled warehouse facility at Ted Stevens Anchorage International Airport (ANC).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210124005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
